DNA

New co-developed product delivers a complete Tier 1 ADME panel coupled with best-in-class AI-driven human pharmacokinetic (PK) projection and integrated compound management —enabling scientists to make lead-optimization-quality decisions starting in hit identification BOSTON, May 26, 2026 /PRNewswire/ -- Ginkgo Bioworks (NYSE: DNA) today announced that its Datapoints offering is launching ADME-One™ , a fully integrated ADME platform for drug discovery teams co-developed with Tangible Scientific  and Inductive Bio . ADME-One delivers a high-throughput Tier 1 ADME (absorption, distribution, metabolism, and excretion) panel paired with best-in-class AI-powered human pharmacokinetic (PK) projection and fully integrated compound management.

Ginkgo Bioworks (DNA) reported Q1 revenues of $19.5M, down nearly 50% year-over-year and badly missing street estimates even after Biosecurity adjustments. Management is pivoting to autonomous labs but refuses to provide revenue guidance, causing analyst estimates to fall further. DNA continues to burn significant cash, with Q1 cash burn at $49M and 2026 guidance of $125M–$150M, leaving $373M in cash and no debt but weakening flexibility.

Ginkgo provides an update on its first quarter financial results following the divestiture of its Biosecurity business BOSTON, May 7, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced its results for the first quarter of 2026 that ended March 31, 2026. The update, including a webcast slide presentation with additional details on the first quarter, as well as supplemental financial information, will be available at investors.ginkgobioworks.com.

Presentation and Q&A session scheduled for post-market on Thursday, May 7, 2026 BOSTON, April 30, 2026 /PRNewswire/ -- Ginkgo Bioworks Holdings, Inc. (NYSE: DNA, "Ginkgo") today announced that it plans to host a presentation and Q&A session reviewing business performance for the first quarter ended March 31, 2026, on Thursday, May 7, 2026, beginning at 4:30 p.m. ET. The presentation details and webcast link will be available on Ginkgo's investor relations website at https://investors.ginkgobioworks.com, and a replay will be made available.